Proteolysis-Inducing Factor in Cancer Cachexia

  • Michael J. Tisdale


Progressive atrophy of skeletal muscle in cancer cachexia leads to reduced power output and weakness (asthenia), resulting in reduced physical activity and a lower quality of life of the cancer patient. Eventually, loss of respiratory muscle becomes so extensive that function becomes significantly impaired, resulting in death through hypostatic pneumonia. Death normally occurs when patients have lost about 35% of their ideal body weight.


Lean Body Mass Cancer Cachexia Simian Immunodeficiency Virus Infection Muscle Protein Degradation Murine Myoblast 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Maltoni M, Fabbri L, Nanni O et al (1997) Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer 5:130–135PubMedCrossRefGoogle Scholar
  2. 2.
    Waage A, Espevik T, Lamvik J (1986) Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients. Scand J Immunol 24:739–743PubMedCrossRefGoogle Scholar
  3. 3.
    Horvath CJ, Desrosiers RD, Sehgal PK et al (1991) Effect of simian immunodeficiency virus infection on tumour necrosis factor-a production by alveolar macrophages. Lab Invest 65:280–286PubMedGoogle Scholar
  4. 4.
    Thompson MP, Cooper ST, Parry BR, Tuckey JA (1993) Increased expression of the mRNA for the hormone-sensitive lipase in adipose tissue of cancer patients. Biochem Biophys Acta 1180:236–241PubMedGoogle Scholar
  5. 5.
    Tisdale MJ (2001) Cancer anorexia and cachexia. Nutrition 17:438–442PubMedCrossRefGoogle Scholar
  6. 6.
    Belizario JE, Katz M, Raw CI (1991) Bioactivity of skeletal muscle proteolysis-inducing factors in the plasma proteins from cancer patients with weight loss. Br J Cancer 63:705–710PubMedGoogle Scholar
  7. 7.
    Bibby MC, Double JA, Ali SA et al (1987) Characterization of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals. J Natl Cancer Inst 78:539–546PubMedGoogle Scholar
  8. 8.
    Beck SA, Tisdale MJ (1987) Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host. Cancer Res 47:5919–5923PubMedGoogle Scholar
  9. 9.
    McDevitt TM, Todorov PT, Beck SA et al (1995) Purification and characterization of a lipid-mobilizing factor associated with cachexia-inducing tumors in mice and humans. Cancer Res 55:1458–1463PubMedGoogle Scholar
  10. 10.
    Todorov PT, McDevitt TM, Cariuk P et al (1996) Induction of muscle protein degradation and weight loss by a tumor product. Cancer Res 56:1256–1261PubMedGoogle Scholar
  11. 11.
    Todorov P, Cariuk P, McDevitt T et al (1996) Characterization of a cancer cachectic factor. Nature 379:739–742PubMedCrossRefGoogle Scholar
  12. 12.
    Todorov PT, Deacon M, Tisdale MJ (1997) Structural analysis of a tumor-produced sulfated glycoprotein capable of initiating muscle protein degradation. J Biol Chem 272:12279–12288PubMedCrossRefGoogle Scholar
  13. 13.
    Choudhary G, Chakel J, Hancock W et al (1999) Investigation of the potential of capillary electrophoresis with off-line matrix-assisted laser desorption / ionization time-of-flight mass spectrometry for clinical analysis: examination of a glycoprotein factor associated with cancer cachexia. Anal Chem 71:855–859PubMedCrossRefGoogle Scholar
  14. 14.
    Schittek B, Hipfel R, Sauer B et al (2001) Dermicidin: a novel human antibiotic peptide secreted by sweat glands. Nat Immunol 2:1133–1137PubMedCrossRefGoogle Scholar
  15. 15.
    Cunningham TJ, Jing H, Akerblom I et al (2002) Identification of the human cDNA for new survival / evasion peptide (DSEP): studies in vitro and in vivo of overexpression by neural cells. Exp Neurol 177:32–39PubMedCrossRefGoogle Scholar
  16. 16.
    Cariuk P, Lorite MJ, Todorov PT et al (1997) Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br J Cancer 76:606–613PubMedGoogle Scholar
  17. 17.
    Carbal Mazano R, Bhargava P, Torres-Duarte A et al (2001) roteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br J Cancer 84:1599–1601CrossRefGoogle Scholar
  18. 18.
    Wang Z, Corey E, Hass GM et al (2003) Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia. Int J Cancer 105:123–129PubMedCrossRefGoogle Scholar
  19. 19.
    Strassman G, Fong M, Kenny JS, Jacob CO (1992) Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89:1681–1684CrossRefGoogle Scholar
  20. 20.
    Fujimoto-Ouchi K, Tamura S, Mori K et al (1995) Establishment and characterization of cachexiainducing and non-inducing clones of murine colon 26 carcinoma. Int J Cancer 61: 522–528PubMedCrossRefGoogle Scholar
  21. 21.
    Soda K, Kawakami M, Kashi K, Miyata M (1995) Manifestations of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin-6. Int J Cancer 62: 332–336PubMedCrossRefGoogle Scholar
  22. 22.
    Yasumoto K, Nukaida N, Harada A et al (1995) Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. Cancer Res 55:921–927PubMedGoogle Scholar
  23. 23.
    Hussey HJ, Todorov PT, Field WN et al (2000) Effect of a fluorinated pyrimidine on cachexia and tumour growth in murine cachexia models: relationship with a proteolysis inducing factor. Br J Cancer 83:56–62PubMedCrossRefGoogle Scholar
  24. 24.
    Lorite MJ, Thompson MG, Drake JL et al (1998) Mechanism of muscle protein degradation induced by a cancer cachectic factor. Br J Cancer 78:850–856PubMedGoogle Scholar
  25. 25.
    Lorite MJ, Cariuk P, Tisdale MJ (1997) Induction of protein degradation by a tumour factor. Br J Cancer 76:1035–1040PubMedGoogle Scholar
  26. 26.
    Lorite MJ, Smith HJ, Arnold JA et al (2001) Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br J Cancer 85:297–302PubMedCrossRefGoogle Scholar
  27. 27.
    Gomes-Marcondes MC, Smith HJ, Cooper JC, Tisdale MJ (2002) Development of an in vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor. Br J Cancer 86:1628–1633PubMedCrossRefGoogle Scholar
  28. 28.
    Wigmore SJ, Todorov PT, Barber MD et al (2000) Characteristics of patients with pancreatic cancer expressing a novel cachectic factor. Br J Surg 87:53–58PubMedCrossRefGoogle Scholar
  29. 29.
    Watchorn TM, Waddell ID, Dowidar N, Ross JA (2001) Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-kB and STAT3. FASEB J 15:562–564PubMedGoogle Scholar
  30. 30.
    Watchorn TM, Waddell I, Ross JA (2002) Proteolysisinducing factor differentially influences transcriptional regulation in endothelial subtypes. Am J Physiol 282:E763–E769Google Scholar
  31. 31.
    Whitehouse AS, Tisdale MJ (2003) Induced expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kB. Br J Cancer 89:1116–1122PubMedCrossRefGoogle Scholar
  32. 32.
    Smith HJ, Lorite MJ, Tisdale MJ (1999) Effect of a cancer cachectic factor on protein synthesis / degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid. Cancer Res 59:5507–5513PubMedGoogle Scholar
  33. 33.
    Smith HJ, Tisdale MJ (2003) Signal transduction pathways involved in proteolysis-inducing factor induced proteasome expression in murine myotubes. Br J Cancer 89:1783–1788PubMedCrossRefGoogle Scholar
  34. 34.
    Hussey HJ, Bibby MC, Tisdale MJ (1996) Novel antitumour activity of 2, 3, 5-trimethyl-6-(3-pyridylmethyl)-l, 4-benzoquinone (CV-6504) against established murine adenocarcinomas (MAC). Br J Cancer 73:1187–1192PubMedGoogle Scholar
  35. 35.
    Whitehouse AS, Khal J, Tisdale MJ (2003) Induction of protein catabolism in myotubes by 15(S)-hydroxyeicosatetraenoic acid through increased expression of the ubiquitin-proteasome pathway. Br J Cancer 89:737–745PubMedCrossRefGoogle Scholar
  36. 36.
    Beck SA, Smith KL, Tisdale MJ (1991) Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res 51:6089–6093PubMedGoogle Scholar
  37. 37.
    Whitehouse AS, Smith HJ, Drake JL, Tisdale MJ (2001) Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res 61:3604–3609PubMedGoogle Scholar
  38. 38.
    Wigmore SJ, Barber MD, Ross JA et al (2000) Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 36:177–184PubMedCrossRefGoogle Scholar
  39. 39.
    Barber MD, Ross JA, Voss AC et al (1999) The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer Br J Cancer 81:80–86PubMedCrossRefGoogle Scholar
  40. 40.
    Evans WK, Makuch R, Clamon GH et al (1985) Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Res 45:3347–3353PubMedGoogle Scholar
  41. 41.
    Whitehouse AS, Tisdale MJ (2001) Downregulation of ubiquitin-dependent proteolysis by eicosapentaenoic acid in acute starvation. Biochem Biophys Res Commun 285:598–602PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • Michael J. Tisdale
    • 1
  1. 1.Pharmaceutical Sciences Research InstituteAston UniversityBirminghamUK

Personalised recommendations